A strategic partnership between Akeada and Biological E. Limited aims to hasten access to QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs) for National Immunization Programs by 2030. MDVs offer cost and logistical benefits, with BE aiming for a manufacturing capacity of 50 million doses yearly to support Takeda’s goal of 100 million doses annually within the decade.
Takeda’s President of Global Vaccine Business Unit, Gary Dubin, highlights the aim to broaden QDENGA’s availability, noting successful launches in private markets and ongoing efforts in public programs. The partnership with Biological E. Limited reinforces this goal by enhancing manufacturing capacity, thus aiding in the global fight against dengue.
Dengue fever, a mosquito-borne viral disease, has seen a significant rise in global incidence rates due to factors like urbanization and climate change. With over 100 countries affected and an estimated 390 million infections annually, regions like Asia bear the brunt of this burden.